Abstract
As research focus in oncology has recently shifted from oral targeted therapy to immunomodulation, the era of successful drug development in bladder cancer has just begun. This has led to unprecedented approval of five immunotherapeutic agents by regulatory agencies for metastatic bladder cancer within a span of 12 months. With an initial triumph of anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) drugs, ongoing efforts are aimed at identification and validation of new druggable immune targets to consolidate the initial gains. In this paper, we review the role of immunotherapy in the treatment of bladder cancer as well as the various emerging immunotherapeutic agents and their possible use in bladder cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 629-645 |
| Number of pages | 17 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 81 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2018 |